2021 CMSC Annual Meeting

Abstracts

Late Breaking-Disease-modifying therapy

Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)

Background: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more...

Read More

Late Breaking-Disease-modifying therapy

B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study

Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS...

Read More

Late Breaking-Disease-modifying therapy

Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment

Background: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing...

Read More

Late Breaking-Quality of life and outcomes

Patient Practices and Experiences during COVID-19 Among Individuals across the United States Enrolled in MS Lifelines Patient Support Program

Background: Research into the impact of COVID-19 on people with MS is ongoing. Objectives: To gain an understanding of COVID-19 practices...

Read More

Late Breaking-Disease-modifying therapy

Sustained B-Cell Depletion By Inebilizumab Is Associated with Decreased Disease Activity in Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder

Background: Inebilizumab is a humanized, affinity-optimized, anti-CD19 monoclonal antibody approved in Japan, South Korea and the USA to...

Read More

Late Breaking-Disease-modifying therapy

The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type

Background: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic,...

Read More

Late Breaking-Disease-modifying therapy

Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab

Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts...

Read More

Late Breaking-Disease-modifying therapy

Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab

Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in...

Read More

Late Breaking-Epidemiology and genetics

Geographic Variance of MS Prevalence in the United States

Background: The etiology of multiple sclerosis (MS) is not fully understood, and the disease may be triggered or exacerbated by...

Read More

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

Synesthesia May be Prevalent in Multiple Sclerosis

Background: Synesthesia is a neurological condition in which information in one sensory domain stimulates another unrelated sensory domain....

Read More